Biogen Surpasses Profit Estimates with Strong Cost Management and Leqembi Sales Surge
Wednesday, 24 April 2024, 10:47
Biogen's Profit Exceeds Expectations
Biogen has once again showcased its financial strength by surpassing quarterly profit estimates, highlighting successful cost reduction strategies.
Leqembi Sales Surge
The sales of Alzheimer's drug Leqembi have soared, bringing in $19 million this quarter compared to $10 million last year, indicating a significant revenue increase.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.